The FDA has posted a summary of Novo Nordisk (NVO) site inspections made over several dates in March of this year at the company’s Drug Substance Manufacturing Site in Kalundborg Sjalland 4400 DK.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk’s Bold Share Repurchase Strategy
- Novo Nordisk downgraded to Hold from Buy at Erste Group
- Eli Lilly’s Weight Loss Drug Mounjaro Finds its Place in Hong Kong
- Novo Nordisk’s (NYSE:NVO) GLP-1 Drugs Could Help Fight Alzheimer’s Disease
- Boeing union rejects latest offer, Tesla reports Q3 beat: Morning Buzz